Drug Trial Radar · NCT05339321
Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
Last checked: Nov 19, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
36
Planned (sponsor's estimate)
Start
Apr 14, 2021
Primary completion
Jul 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adoptive cell therapy with TCR-T cells targeting HBV antigens represents an innovative opportunity for treatment of HBV-related HCC. SCG101 is a genetically modified autologous TCR-T cell therapy with a natural high-avidity TCR directed towards the HLA-A\*02-restricted HBsAg peptide. This is a phase 1 clinical study of SCG101 alone and with PD-1/PD-L1 checkpoint inhibitors in HBV-related HCC.
Conditions
- Hepatocellular Carcinoma
Interventions
SCG101Genetic
SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
PD1/PD-L1 checkpoint inhibitorBiological
Commercially approved for HCC treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT)Time frame: 28 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, China · Recruiting
The First Hospital of China Medical University
Shenyang, China · Recruiting
The Sixth People's Hospital of Shenyang
Shenyang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.